Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 4/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.50 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166243 | 0.92 | MET (0.57) | METKDRPDGFRAPTK2BPTK2 | |
| SCHEMBL16242280 | 0.89 | MET (0.41) | METKDRPDGFRAPTK2BPTK2 | |
| SCHEMBL20022422 | 0.87 | MET (0.62) | METKDRPTK2BPTK2IGF1R | |
| SCHEMBL18163465 | 0.86 | MET (0.58) | METKDRPTK2BPTK2IGF1R | |
| SCHEMBL20022421 | 0.86 | MET (0.58) | METKDRPTK2BPTK2IGF1R | |
| SCHEMBL20022428 | 0.86 | MET (0.58) | METKDRPTK2BPTK2IGF1R | |
| SCHEMBL20022458 | 0.86 | MET (0.58) | METPTK2BPTK2SYK | |
| SCHEMBL165339 | 0.85 | MET (0.62) | METPTK2BPTK2SYK | |
| SCHEMBL18163636 | 0.85 | MET (0.58) | METKDRPTK2BPTK2IGF1R | |
| SCHEMBL20022429 | 0.85 | MET (0.58) | METKDRPTK2BPTK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | claimed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | claimed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | claimed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | MET 8/4885KDR 30/4885PDGFRA 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.